近日,辉瑞公司公布了2025年第一季度财务业绩,并重申了全年财务指引。尽管面临复杂市场环境,公司通过强化研发组织与成本优化措施,实现了稳健的盈利增长。财务亮点总收入:137亿美元,同比下降8%(按固定汇率计算下降6%),主要因Paxlovid收入减少(同比下降75%),但部分被Vyndaqel系列(增长33%)、Comirnaty(增长62%)等产品抵消。调整后每股收益(EPS):0.92美元,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.